Published in Anticancer Drugs on November 01, 2006
Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal (2009) 2.33
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol (2009) 0.94
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs (2009) 0.92
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Transl Oncol (2012) 0.83
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood (2014) 0.82
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. Cancer Chemother Pharmacol (2011) 0.80
Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol (2016) 0.75
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res (2003) 2.80
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res (2005) 1.62
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother (2008) 1.11
Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol (2007) 1.07
UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther (2009) 1.01
Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. Toxicon (2002) 0.97
Glucose 6-phosphate dehydrogenase overexpression models glucose deprivation and sensitizes lymphoma cells to apoptosis. Antioxid Redox Signal (2006) 0.95
Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Mol Cancer Ther (2002) 0.95
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol (2009) 0.94
The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest (2007) 0.93
Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem (2004) 0.92
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol (2013) 0.92
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs (2009) 0.92
Correlates of imexon sensitivity in human multiple myeloma cell lines. Leuk Lymphoma (2006) 0.90
Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anticancer Drugs (2002) 0.90
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides (2006) 0.89
Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. Mod Pathol (2009) 0.89
Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance. Exp Ther Med (2012) 0.89
alpha6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation. Int J Radiat Biol (2007) 0.88
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2005) 0.88
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Invest New Drugs (2008) 0.88
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol (2007) 0.86
Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. J Pharmacol Exp Ther (2009) 0.84
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer (2010) 0.83
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Transl Oncol (2012) 0.83
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest New Drugs (2006) 0.83
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorg Med Chem Lett (2009) 0.82
Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Mol Cancer Res (2012) 0.82
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Exp Ther (2007) 0.82
Pyrimidoquinazoline-based antitumor agents. Design of topoisomerase II to DNA cross-linkers with activity against protein kinases. J Med Chem (2002) 0.81
Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer (2008) 0.81
Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem Pharmacol (2007) 0.80
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. Cancer Chemother Pharmacol (2011) 0.80
Gender difference in systemic oxidative stress and antioxidant capacity in current and former heavy smokers. Cancer Epidemiol Biomarkers Prev (2012) 0.79
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther (2015) 0.79
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother Pharmacol (2010) 0.78
The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Invest New Drugs (2013) 0.76
Characterization of a membrane-active anti-tumor agent, UA8967. Invest New Drugs (2012) 0.75
Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells. Anticancer Res (2011) 0.75
Mood alterations in patients treated with chlorambucil. Clin Lymphoma (2003) 0.75
Cytotoxic lignans from Larrea tridentata. Phytochemistry (2005) 0.75
Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. J Immunol (2007) 0.75